16 September 2024
At the annual European Society for Medical Oncology (ESMO) congress in Barcelona, Spain, Illumina brought together oncologists, patient advisory groups, clinicians, and researchers to discuss the growing evidence on the benefits of comprehensive genomic profiling (CGP) using liquid biopsy, and how it can help to inform therapy decisions and improve patient care.
This revolutionary technique uses a blood test to detect circulating tumor DNA, which is then sequenced to assess multiple biomarkers in numerous tumor types using a single next-generation sequencing assay. This process is less invasive for patients, requiring a one-time test rather than multiple biopsies, which can add to the patient’s discomfort and prolong the wait for a diagnosis.
